The superparamagnetic nanoparticles carrying the E1A gene enhance the radiosensitivity of human cervical carcinoma in nude mice

Molecular Cancer Therapeutics

Volumn 9, Issue 7, 2010, Pages 2123-2130

  Shen, Liang Fang ^a   Chen, Jia ^a   Zeng, Shan ^a   Zhou, Rong Rong ^a   Zhu, Hong ^a   Zhong, Mei Zuo ^a   Yao, Ruo Jing ^a   Shen, Hong ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

E1A PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; PROTEIN P53; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; DEXTRAN; FERRIC ION; FERRIC OXIDE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG MECHANISM; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; IRRADIATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG SCREENING; FEMALE; GENE THERAPY; GENETICS; HELA CELL LINE; MAGNETISM; METABOLISM; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PATHOLOGY; PROCEDURES; UTERINE CERVICAL NEOPLASMS;

ADENOVIRUS E1A PROTEINS; ANIMALS; BLOTTING, WESTERN; COMBINED MODALITY THERAPY; DEXTRANS; FEMALE; FERRIC COMPOUNDS; GENETIC THERAPY; HELA CELLS; HUMANS; MAGNETICS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954591770     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1150     Document Type: Article

References (43)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Kim TJ, Lee JW, Song SY, et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer 2006;94:1678-82.
3. Weibo Yin, Xizhi Gu. Therapeutic radiology of tumor. pp. 889-933Beijing (China): Medical University of Union, Press; 2003.
4. Li Z, Day CP, Yang JY, et al. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res 2004;64:9080-5. (Pubitemid 39665521)
5. Chen H, Hung MC. Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene. J Biol Chem 1997;272:6101-4.
6. Shen L, Zeng S, Chen J, et al. E1A inhibits the proliferation of human cervical cancer cells (HeLa cells) by apoptosis induction through activation of HER-2/Neu/Caspase-3 pathway. Med Oncol 2008;25:222-8.
7. Serrano-Olvera A,Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M, De la Garza-Salazar J. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006;32:180-90.
8. Shen L, Shui Y, Wang X, et al. EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy. BMC Cancer 2008;8:232.
9. Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, et al. HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004;4:59.
10. Sharma A, Pratap M, Sawhney VM, Khan IU, Bhambhani S, Mitra AB. Frequent amplification of C-erbB2 (HER-2/Neu) oncogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections. Oncology 1999;56:83-7. (Pubitemid 29043901)
11. Lee CT, Park MY, Kim DR, et al. Blockade of NF-κB activation by IêB-gene therapy enhances radiation sensitivity and abolishes acquired resistance to radiation. Molecular Medicine 2009;2:471-5.
12. Guha C, Guha U, Tribius S, et al. Antisense ATM gene therapy: a strategy to increase the radiosensitivity of human tumors. Gene Ther 2000;7:852-8.
13. Zhang G, Liu T, Chen YH, et al. Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo. Clin Cancer Res 2009;15:201-7.
14. Li Z, Xiang J, Zhang W, et al. Nanoparticle delivery of anti-metastatic NM23-1 gene improves chemotherapy in a mouse tumor model. Cancer Gene Ther 2009;16:423-9.
15. Ma HL, Qi XR, Maitani Y, Nagai T. Preparation and characterization of superparamagnetic iron oxide nanoparticles stabilized by alginate. Int J Pharm 2007;333:177-86.
16. Cao ZG, Zhou SW, Sun K, Lu XB, Luo G, Liu JH. Preparation and feasibility of superparamagnetic dextran iron oxide nanoparticles as gene carrier. Ai Zheng 2004;23:1105-9.
17. Medina LA, Herrera-Penilla BI, Castro-Morales MA, et al. Use of an orthovoltage X-ray treatment unit as a radiation research system in a small-animal cancer model. J Exp Clin Cancer Res 2008;27:57.
18. Shen H, Huang G, Hadi M, et al. Transforming growth factor-β1 downregulation of Smad1 gene expression in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2003;285:G539-46.
19. Peng ZZ, Hu GY, Shen H, et al. Fluorofenidone attenuates collagen I and transforming growth factor-β1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells. Nephrology (Carlton) 2009;14:565-72.
20. Shen H, Zhang M, Minuk GY, Gong Y. Different effects of rat interferon α, β and γ on rat hepatic stellate cell proliferation and activation. BMC Cell Biol 2002;3:9.
21. Basarkar A, Singh J. Nanoparticulate systems for polynucleotide delivery. Int J Nanomedicine 2007;2:353-60.
22. Jabr-Milane L, van Vlerken L, Devalapally H, et al. Multi-functional nanocarriers for targeted delivery of drugs and genes. J Control Release 2008;130:121-8.
23. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318.
24. Scherer F, Anton M, Schillinger U, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002;9:102-9.
25. Madhusudan S, Tamir A, Bates N, et al. A multicenter phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 2004;10:2986-96.
26. Frisch SM. E1A as a tumor suppressor gene: commentary re S. Madhusudan et al. A multicenter phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 2004;10:2905-7.
27. Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001;19:3422-33.
28. Ueno NT, Bartholomeusz C, Herrmann JL, et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000;6:250-9.
29. Lewis AM, Su M, Doty J, Chen Y, Pardo FS. Relationship between intrinsic radiation sensitivity and metastatic potential. Int J Radiat Oncol Biol Phys 1996;34:103-10. (Pubitemid 26019958)
30. Wang XL, Qian XL, Zhao QZ, Xu ZG, Tang PZ. [Effect of E1A gene on in vitro growth inhibition and radiochemosensitivity of lymph node metastasis cells of human head and neck squamous cell carcinoma]. Ai Zheng 2003;22:1140-6.
31. Cao N, Li S, Wang Z, et al. NF-κB-mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res 2009;171:9-21.
32. Sato S, Kajiyama Y, Sugano M, et al. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys 2005;61:203-11.
33. Uno M, Otsuki T, Kurebayashi J, et al. Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma. Int J Cancer 2001;94:474-9.
34. Akamatsu M, Matsumoto T, Oka K, et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003;57:1323-7.
35. Chiou SK, White E. p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. J Virol 1997;71:3515-25.
36. Querido E, Teodoro JG, Branton PE. Accumulation of p53 induced by the adenovirus E1A protein requires regions involved in the stimulation of DNA synthesis. J Virol 1997;71:3526-33.
37. Warenius HM, Jones M, Gorman T, et al. Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity. Br J Cancer 2000;83:1084-95.
38. Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemosensitivity. Apoptosis 2009;14:597-606.
39. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117-29.
40. Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, Terrian DM. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 2007;6:595-605. (Pubitemid 46440434)
41. Eschrich S, Zhang H, Zhao H, et al. Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys 2009;75:497-505.
42. Chen Y, DeWeese T, Dilley J, et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001;61:5453-60.
43. Martin-Duque P, Sanchez-Prieto R, Romero J, et al. In vivo radiosensitizing effect of the adenovirus E1A gene in murine and human malignant tumors. Int J Oncol 1999;15:1163-8.